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Parkinson’s disease (PD) patients display low novelty seeking scores on the Tridimensional Personality Questionnaire (TPQ),
which may reflect the low dopamine function that characterises the disease. People with PD also display raised harm avoidance
scores. Due to these and other observations, a “parkinsonian personality” has been suggested. However, little is known about how
these features relate to cognitive and aﬀective disorders, which are also common in PD. We examined links between TPQ scores
and performance on an attentional orienting task in a sample of 20 people with PD. In addition, associations between TPQ and
depression and anxiety scores were explored. It was found that novelty seeking scores were significantly correlated with a reaction
time measure of attentional orienting to visual novelty. Harm avoidance scores were significantly correlated with anxiety, but not
depression scores. These findings extend our understanding of how temperament interacts with cognitive and aﬀective features of
the disorder.
1. Introduction
Parkinson’s disease (PD) is primarily considered a neuro-
logical disease that produces movement disorders. However,
patients with PD also tend to show a range of cognitive and
psychiatric symptoms. In addition, a particular “parkinso-
nian personality” has often been described, which appears
to be premorbid to neurological symptoms [1, 2] and may
therefore be a temperament feature of the disease. At present,
the extent to which such personality features contribute to
the cognitive and aﬀective components of the disease is
poorly understood.
The primary pathology in the brains of PD patients is
the loss of dopamine-producing cells in the substantia nigra
[3]. Physiologically, the importance of the substantia nigra
is in its dopaminergic projections to the striatum, which is
one of the three main dopamine systems in the brain [4]. In
PD patients, dopamine levels in this area have been observed
to be only 10% of the normal level [5]. Therefore, PD is
often considered as a disease that provides a model of low
dopamine function in the human brain. Consequently, PD is
of particular interest when considering theories that include
the functional significance of dopamine.
One such theory, Cloninger et al.’s psychobiological
approach to personality [6–9], posits that dopamine systems
in the brain are the biological substrate of the temperament
trait of novelty seeking. This “tridimensional” approach to
personality measurement also proposes two further traits;
harm avoidance (linked to serotonin) and reward depen-
dence (linked to noradrenalin) [6]. However, later factor
analytic studies revealed a fourth minor factor called persis-
tence, which had formally been part of reward dependence
[8]. Following the confirmation of the genetic structure of
these four temperament dimensions, additional personality
features were identified by Cloninger and colleagues which
mature in adulthood. In fact, three additional character
dimensions have been proposed which are influenced by
insight learning, these are self-directedness, cooperativeness,
and self-transcendence [9]. This psychobiological model of
temperament and character has continued to evolve and
is supported from a range of clinical and neuroscientific
studies [7]. In particular, physiology-based research has
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focused on the temperament dimensions of novelty seeking,
harm avoidance, and reward dependence, due to their
supposed genetic basis and neurochemical substrates. It is
of course reductionist and an over simplification to equate
a personality trait directly with a single neurotransmitter
substance. There is a large degree of cross-over between
the diﬀerent circuits and systems in the brain, and highly
complex neurotransmitter interactions at the cellular level
[10]. Nevertheless, it is accepted that PD is primarily a
dopamine deficiency disorder [11] and that novelty seeking
is more closely linked to dopamine function than any of the
other neurochemical systems [12]. Therefore, in regard to
PD, it is the temperament trait of novelty seeking which has
received particular research attention. Indeed, patients with
PD have been shown to display significantly lower novelty
seeking scores than disability matched patients [13]. In a
follow-up study, the role of dopamine was confirmed by the
finding that 18 F Dopa striatal uptake in PET scans correlated
with novelty seeking scores in PD patients [14]. Further
research has confirmed this link between low novelty seeking
and PD [15, 16].
The distinctive personality of PD patients has been
recognized for many years. As early as 1880, Charcot had
described low motivation in patients with PD [17]. In
addition, patients with PD have been described as displaying
“premature social ageing.” This was based on the observation
that many PD patients have few friends, reduced social
involvement, few hobbies, and often prefer to spend time on
solitary tasks [18, 19]. Furthermore, it has long been noted
that PD patients are more likely to be nonsmokers than the
general population. From this, it has been suggested that
premorbidly, PD patients are less hedonistic or more self-
controlled than the average person [2].
Cognitive impairments, particularly involving frontal
lobe function are also widely described in PD [20, 21].
However, it is possible that the cognitive impairments are in
part manifestations of the parkinsonian personality profile.
Recently it has been noted that frontal lobe-associated cog-
nitive task performance correlates with personality variables
in patients with PD, and it has been suggested that both
may reflect a common mechanism [22]. In this respect,
novelty seeking may be of particular interest, as it is partly
defined as “a heritable bias in the activation or initiation of
behaviours such as frequent exploratory activity in response
to novelty” [9]. It could therefore be suggested that novelty
seeking would be associated with orientation and attention
in cognitive tasks. Indeed, it has been shown that there are
significant correlations between novelty seeking scores and
performance of visual attention tasks in healthy individuals
[23]. In particular, orientation to novelty has traditionally
been considered as crucial to adaptation and action within
a changing environment [24]. We may therefore hypothesise
that impaired performance of cognitive tasks involving
attention to novelty, will be linked to personality factors in
patients with PD, in particular, novelty seeking.
Aﬀective disorders are also common in patients with
PD. Anxiety has been shown to be more prominent in PD
than in healthy samples [25]. However, it is unclear whether
this is a response to, or a symptom of, the disease itself.
While anxiety varies with motor fluctuations and correlates
with disease progression [26], this could be viewed as either
indicating a neurobiological or a reactive mechanism. In
support of a neurobiological cause is the observation that
high levels of anxiety are linked to a serotonin transporter
gene polymorphism in patients with PD [27]. Higher levels
of depression were also found to be linked to the gene
polymorphism, highlighting the fact that anxiety in PD tends
to be comorbid with depressive symptoms, and that both
may have a serotonergic basis.
Considering depression in PD, diﬀerent studies have
produced diﬀerent estimates of its prevalence and a variety
of theories are available to explain its occurrence. Prevalence
estimates have varied between 4% and 70% [28]. It is
known that serotonergic function is impaired in PD [29],
and this is a likely neurochemical substrate of aﬀective
aspects of the disease [30]. For example, it has been shown
using transcranial sonography that there are morphological
changes to the serotonergic dorsal raphe in depressed but not
nondepressed PD patients [31].
Serotonergic function is also thought to underlie
Cloninger’s temperament feature of harm avoidance. In
addition to the previously described association between PD
and low novelty seeking, it is perhaps not surprising then that
a relationship between PD and high harm avoidance scores
has also been described, an observation that the authors
attribute to the presence of depression [32]. Indeed, harm
avoidance scores have been found to positively correlate with
depression severity in patients with PD [33]. Nevertheless,
the relationship between harm avoidance and depression in
PD is not well understood.
In this investigation we sought to examine the relation-
ship between the personality dimension of harm avoidance
and aﬀective symptoms in patients with PD.We hypothesised
that within a sample of PD patients, harm avoidance scores
would be correlated with depression and anxiety scores.
Furthermore, to examine the relationship between visual
attention and the trait of novelty seeking in the same
sample, we developed a method to measure how novel
visual events influence attention. This was an adaptation
of the attentional cueing paradigm [34], a reaction time
task often used in experimental psychology. In the standard
version, arrowheads presented at the centre of a display
facilitate response times to stimuli that later appear at the
cued location. Although such tests are widely used, they
do not involve orientation to visual novelty. We used a
version that we adapted ourselves in which visual novelty
was manipulated so that its influence on attention could be
measured with reaction times. We hypothesised that within
our sample of PD patients, the trait of novelty seeking would
be correlated with task performance.
2. Method
2.1. Participants. A total of 20 PD patients participated in
this study, 11 of these were female. All were patients of
the National Hospital for Neurology and Neurosurgery in
London, and the diagnoses of idiopathic PD were made by
a consultant neurologist specialising in movement disorders.
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The mean age of the patients was 68.5 years (SD = 9.4). The
sample had a mean Hoehn and Yahr [35] stage of 1.9 (range
1–4), indicating a wide range of disease progression. Thirteen
healthy control subjects also participated; all were volunteers
who responded to advertisements. Ten of the control subjects
were female. The mean age of the control sample was 69.7
years (SD = 9.1). There was no significant diﬀerence between
the patients and controls for age (t(31) = .38, P = .710).
2.2. Materials and Apparatus. For the assessment of per-
sonality, the Tridimensional Personality Questionnaire was
employed [6]. This measures three personality dimensions,
novelty seeking, harm avoidance, and reward dependence.
The hospital anxiety and depression scale was employed to
measure severity of aﬀective symptoms [36]. Although this is
a brief measure, it is well suited to the current study as it was
originally developed for use with medical outpatient samples
[37] and has been validated for use with PD patients [38].
To administer the experimental task, a laptop computer with
a colour 12.1′′ LCD monitor was used. The experimental
task was implemented with the Visual Basic programming
language. Details of the task are given below.
2.3. The Experimental Task. To measure attention to novelty,
participants were required to make a simple button press
response to a white dot appearing on the laptop screen. This
white dot appeared either to the left or right of a central
cross. A pair of coloured shapes always appeared 200msecs
before the white dot, one on either side of the central
cross (see Figure 1). These two coloured shapes appeared
simultaneously and always in the same two locations. One
of the shapes was always a light brown square. The other
shape was varied such that a totally novel, diﬀerent coloured
shape, would often be substituted for the previous shape.
The substitutions occurred randomly every four to seven
trials. The coloured shapes always appeared as background
to the target white dot. Therefore a typical trial involved the
simultaneous display of two coloured shapes, one to the left
and one to the right, followed one fifth of a second later by
the target white dot, in front of one of the coloured shapes.
The participants’ task was to press the button as soon as they
saw the white dot.
The location of the shape stimuli alternated randomly
left to right, independently of the side that the target
white dot would appear on. The shapes were therefore
irrelevant to task performance, as shifting attention to either
would confer no advantage in predicting the location of the
white dot. However, if orientation of attention is influenced
spontaneously then participants may orient their attention
to the novel stimuli that is being displayed. If they did, and
the white dot appeared there (200msecs later), this might
produce faster response times as their attention is already at
the correct location. Conversely, if they spontaneously orient
their attention to the novel stimuli (the coloured shape) and
the white dot target appears on the other side (it is a 50 : 50
chance) then response times would likely be slowed as their
attention has been diverted to the wrong location.
Figure 1: Representation of the sequence of events of a single trial
in the novelty attention task.
On 14% of the trials the target stimulus was not shown
and a three-second delay was inserted before the next trial
began. This was done to stop participants getting into the
habit of just pressing the button each trial, as some were
“blanks” they had to wait until the white dot appeared before
pressing the button. If the response button was pressed on
those “blank” trials where no target white dot was present,
the computer emitted a tone and the word “error” was
displayed on the screen.
After each trial the shape stimuli and white dot target
disappeared and there was a one-second delay before the
start of the next trial. Reaction times and number of errors
were automatically recorded to a computer file. A visual
representation of the temporal sequence of events in a typical
trial is shown in Figure 1.
2.4. Procedure. All participants were contacted by telephone
and an appointment made for their research participation.
The assessment was conducted in the participant’s own
home. All participants contributed data on the novelty atten-
tion task performance; however, clinical data on aﬀective
symptoms and personality data was only collected on the
PD patients. All participants provided informed and written
consent, and the project was approved by the local research
ethics committee.
PD patients were interviewed after an overnight with-
drawal (approximately 11 hours) of their antiparkinsonian
medication to ensure that they were in a hypodopaminergic
state. During the interview, basic demographic and clinical
information was collected. Next, the experimental task was
administered. Participants sat approximately 70 cm from the
laptop screen. In each location, dim lighting was employed
to enhance the visibility of the display. One finger of
the dominant hand was held over a microswitch and the
participant was told to press the button as quickly as possible
whenever they saw a white dot appear either to the left or
right of the central cross. They were told to try and keep their
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Table 1: Response times (and SDs) in milliseconds for the PD and control participants in the novelty attention task.
Parkinson’s Control
Level of novelty Novel Repetitive Novel Repetitive
1 417 (85) 425 (85) 377 (60) 383 (63)
2 409 (90) 416 (83) 370 (54) 380 (60)
3 411 (95) 415 (89) 361 (47) 371(58)
4 420 (92) 416 (88) 372 (59) 380 (56)
5 409 (94) 416 (96) 368 (60) 386 (69)
6 398 (96) 418 (89) 375 (69) 382 (71)
7 406 (99) 418 (92) 366 (55) 371 (55)
“Novel” indicates when the target appeared in conjunction with the novel stimuli and “Repetitive” indicates when it appeared in conjunction with the repetitive
stimuli. The level of novelty ranges from when a novel shape was shown for the very first time (1) to when it had been shown 7 times.
fixation on this cross but that coloured shapes would appear
in the background and that these would change occasionally.
Responses were made via a button pad linked to a digital
timing card in the computer. Input from the key was sampled
at the rate of 1000Hz. Two blocks of trials were performed.
Each block involved 40 novel stimuli. There were 200 trials
in each block. Each block took approximately 8 minutes
to complete. Other cognitive assessments were performed
which are not reported here.
2.5. Statistical Analyses. For all continuous data, the nor-
mality of distribution assumptions was verified with
Kolmogorov-Smirnov one sample tests. Parametric tests
were used with normally distributed variables and nonpara-
metric equivalents when data was nonnormally distributed.
To compare RTs on the novelty attention task, a mixed
model ANOVA was used. For all statistically significant
eﬀects in the ANOVA calculations, estimates of eﬀect size
are provided as partial Eta2 statistics. Where t-tests were
employed, eﬀect sizes are reported as Cohen’s d. To assess
associations between variables and test our main hypotheses,
Pearson bivariate correlation statistics were employed. For all
inferential statistics, a value of P < .05 (two-tailed) was taken
to indicate significance. All calculations were performed with
PASW Statistics 18 [39].
3. Results
The novelty attention task is analysed first, followed by
tridimensional personality questionnaire scores and hospital
anxiety and depression scale scores. Finally, associations
between the various measures are considered, as well as
associations with disease progression.
For the novelty attention task, data from the first seven
trials in each block were excluded, as they did not involve
a novel change of stimulus. In addition, trials that occurred
immediately after a withheld response were excluded. To
control for anticipatory responding or lapses of attention,
RTs of less than 100msecs or more than 1000msecs were
excluded. From the remaining datasets, averages were calcu-
lated for the location of the target (either in conjunction with
the repetitive or novel stimuli) and for the level of novelty.
Level of novelty was defined as the number of times that
the participant had seen the shape, including the current
trial. Therefore, level of novelty ranged from 1–7, with 1
being a shape that was displayed for the first time. For each
participant there weremore data points for level of novelty 1–
4 than for 5, 6, or 7. For this reason, mean rather thanmedian
averages were used to summarise the raw data as these are
considered more appropriate for unequal datasets [40].
Response times in all conditions for all participants are
shown in Table 1. To analyse the eﬀect of novelty on response
times, data was entered into a mixed model ANOVA, with
group as a between subjects factor, within subject factors
were location (novel or repetitive) and level of novelty (how
often the novel shape had been presented). In order to
compare the eﬀect of novelty, the data points were averaged
to provide three main groups of novelty level, when the
novel shape first appeared, the mean of the responses for
the 2nd and 3rd presentation, and the mean of the 4th to
7th presentations. The response times using these groupings
are shown in Figure 2 and were analysed as described above.
There was no main eﬀect of group (F (1,31) = 2.14, P = .154)
and the interactions involving group membership were all
non-significant. There was a main eﬀect of location (F (1, 33)
= 9.40, P = .004, partial Eta2 = .223) and of novelty (F (2,62)
= 4.31, P = .018, partial Eta2 = .122). The first presentation
resulted in response times approximately 9msecs slower than
either the second set (novelty level 2 and 3) or the third
set (novelty level 4, 5, 6, and 7). The exact mean RT values
in msecs were 408, 399, and 399, respectively. A planned
contrast was performed to compare RTs when the novel
stimulus was first presented with the combined 2nd and 3rd
presentation RTs, the diﬀerence was statistically significant,
F (1,31) = 9.26, P = .005, partial Eta2 = .230). However, the
diﬀerence in RTs from the 1st presentation to the combined
4th, 5th, 6th, and 7th presentations was not statistically
significant.
Absolute levels of errors (responding in the absence of
a stimulus) were low with several participants making no
errors at all, and so error distributions were nonnormal. For
this reason, medians, rather than means, are reported. The
PD sample made a median of 3 errors (range = 0–23) and
the control group made a median of 4 errors (range = 0–
9), this diﬀerence was not significant (Mann-WhitneyU test,
P = .896).
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Table 2: Correlation coeﬃcients and P values for the associations between temperament dimensions in the PD sample with cognitive and
aﬀective measures.
RT diﬀerence Depression Anxiety
Novelty seeking −.505, P = .023 .004, P = .987 −.116, P = .625
Harm avoidance −.238, P = .313 .309, P = .186 .508, P = .022
Reward dependence .001, P = .996 −.378, P = .100 −.436, P = .055
Figure 2: Comparison of the PD and control participants for
response times when the target stimuli appeared in the repetitive or
novel location and by how many times the novel stimuli had been
presented (level of novelty).
3.1. Anxiety-Depression Scores and Temperament. The PD
sample had a mean novelty seeking score of 13.9 (SD = 4.8),
the mean harm avoidance score was 18.7 (SD = 7.3), and
the mean reward dependence score was 16.8 (SD = 4.0). On
examination of the HADS scale scores, it was found that the
mean score for depression was 4.8 (SD = 3.5, range = 1–15)
and the mean score for anxiety was 7.3 (SD = 4.4, range =
2–19). Using the standard cut score of 8 [36], 3/20 (15%)
of the PD patients would be considered as probable cases
of depressive disorder. Similarly with the same cut score for
anxiety, 8/20 (40%) of the PD patients would be considered
as probable cases of anxiety disorder. Independent group t-
tests revealed that there were no significant diﬀerences for
anxiety or depression scores whenmale PD participants were
compared with the female participants. Although there were
no statistically significant sex diﬀerences for novelty seeking
or reward dependence, it was found that the female PD
patients had significantly higher levels of harm avoidance
(female mean = 22.1, SD = 7.0, male mean = 14.4, SD = 5.5;
t(18) = −.266, P = .016, d = 1.23).
To test our hypotheses that harm avoidance scores would
be associated with depression and anxiety scores in the PD
patients, correlation coeﬃcients were calculated. These are
shown in Table 2. It can be seen that there was a significant
Figure 3: Comparison of Tridimensional Personality Questionnaire
scores for PD participants with or without probable depression or
anxiety.
positive association between harm avoidance and anxiety
severity scores; however, no significant association was
detected with depression severity scores. There were no
significant correlations between novelty seeking scores and
depression or anxiety scores. The association between reward
dependence and anxiety was approaching, but did not reach
statistical significance. To further examine the relationship,
those cases scoring above the cut scores for depression and
anxiety were identified. Their TPQ scores are compared with
those scoring below the cut scores in Figure 3. It can be
seen that those PD participants scoring positive for probable
anxiety disorder scored higher than the other patients for
harm avoidance, and that this diﬀerence was statistically
significant, t(18) = 3.53, P = .002, and d = .70. Furthermore,
the same participants scored lower on reward dependence, a
diﬀerence that was also statistically significant, t(18) =−2.37,
P = .029, and d = 1.06. There was no significant diﬀerence
for novelty seeking scores. A similar pattern of diﬀerences
is seen when comparing those with and without probable
depression. The three patients with probable depression
appeared on visual inspection to score higher on harm
avoidance and lower on reward dependence. However, no
inferential statistical analysis was attempted due to the small
sample size (3 verses 17).
Returning to the novelty attention task, Figure 2 shows
that there is a tendency for RTs to be larger for the 1st
presentation of the novel stimuli than the combined 2nd
and 3rd presentation RTs. This is true for the conditions in
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which the target stimuli appeared in either the repetitive or
novel location, but particularly in the latter. Indeed, for the
full sample, mean response times when the novel stimuli
was first presented (in conjunction with the target) were
approximately 9msecs longer than for when it was presented
the 2nd/3rd time (401.7msecs (SD = 77) compared to
392.6msecs (SD = 80)). As described above, this diﬀerence
is statistically significant, and implies that the presence of a
novel stimulus produces a measurable eﬀect on responding.
The diﬀerence between these two RTs could therefore indi-
cate an overall eﬀect of novel stimuli on responses. To test our
hypothesis that attention to novelty would be correlated with
novelty seeking, the diﬀerence between 1st presentation and
the combined 2nd and 3rd presentation response times when
the target appeared in conjunction with the novel stimuli
were calculated for each patient. The correlations between
this diﬀerence statistic and temperament dimensions on the
TPQ are also shown in Table 2. It can be seen that there was a
significant negative correlation between novelty seeking and
the RT diﬀerence statistic, indicating that patients with high
novelty seeking scores had smaller diﬀerence statistics. There
were no significant correlations with the other temperament
dimensions of harm avoidance and reward dependence.
Finally, the eﬀect of disease severity on temperament,
aﬀective and cognitive performance scores was investigated.
Themedian Hoehn and Yahr disease severity score [35] was 2
(range 1–4), this was used to divide the PD sample into those
with relatively early progression (stages 1 and 1.5, unilateral
symptoms only, n = 8) and those with more advanced
disease (stages 2–4, bilateral symptoms, n = 12). It was found
that there were no significant diﬀerences between the groups
for any of the temperament dimensions, anxiety, depression,
or the diﬀerence statistic used to measure the impact of
novelty on attention. This was true even if a higher disease
progression cutoﬀ was selected which compared the six most
advanced cases with the 14 less advanced cases.
4. Discussion
We report statistically significant cognitive and aﬀective
correlates of temperament dimensions in people with PD.
Using the tridimensional personality questionnaire [6] we
found that novelty seeking was significantly correlated with
a measure of the eﬀect of visual novelty on attention. In
addition, harm avoidance was significantly correlated with
anxiety scores. These two relationships were as hypothesised.
However, we also hypothesised that depression would be
correlated with harm avoidance, but this was not found to
be so. The association between harm avoidance and anxiety
was also confirmed with group mean comparisons. The PD
participants with probable anxiety disorder had significantly
higher harm avoidance scores than those without probable
anxiety disorder. Using the same group comparison it was
found that reward dependence scores were significantly lower
in those PD participants with probable anxiety. None of the
features studied in the participants with PD were found to be
related to disease progression.
We found a relationship between the underlying concept
embodied in the definition of novelty seeking and an exper-
imentally derived measure of responses to visual novelty.
We have previously shown that novelty seeking scores are
associated with eﬃciency of parallel visual processing in a
healthy control sample [23]. However, in the current study a
cognitive association has been demonstrated which directly
links to novelty, and in a sample of PD patients, individuals
considered to be low on the trait of novelty seeking. Although
in our own PD sample we found no specific evidence
for low novelty seeking scores. Nevertheless, the finding
of low novelty seeking among patients with PD has been
demonstrated previously [13–16].
Using the custom-designed attentional task, it was found
that both the PD and control participants displayed a
significant novelty-related location eﬀect. That is, responses
were generally faster when the target appeared in conjunction
with the novel stimulus. The procedure is therefore capable
of measuring the influence of novel visual events on response
times. It was also found that there was a significant level
of novelty eﬀect. That is, responses tended to be relatively
faster on 2nd and 3rd (combined) and 4th to 7th (combined)
presentations of the novel stimulus relative to the 1st pre-
sentation. This eﬀect occurred whether the target appeared
in conjunction with the novel or repetitive stimulus. It is
not possible to definitely say whether this eﬀect occurred
because the novel stimuli slowed or enhanced responses.
However, we can assume that the novel stimulus was able to
attract attention, which consequently influenced RTs. Similar
eﬀects have been observed in other cognitive experimental
procedures when novel elements “pop-out” and familiar
items “sink-in” to the display [41]. There was also a main
eﬀect of target location. Response times in general were
significantly faster when the target appeared in conjunction
with the novel, relative to the repetitive, stimuli. In the
paradigm of attentional cueing developed by Posner [34],
faster response times at a cued location are taken to indicate
that attention is orientated to the location prior to the
presentation of the target, hence faster response times. The
current findings show that novelty can act to unconsciously
cue attention to a spatial location. This supports the theory
of novel “pop-out” which argues that novel visual elements
attract rapid covert shifts in attention [41, 42].
In order to obtain a single measure of the eﬀect of
the novel stimulus on responding, the diﬀerence between
response times from the 1st presentation and combined
2nd-3rd presentations for targets appearing in conjunction
with the novel event were calculated. This gives a simple
measure of the impact of novelty on the performance of
individual participants. When this statistic was compared to
personality dimensions with the Tridimensional Personality
Questionnaire, it was found that there was a significant
negative correlation with novelty seeking. Those patients
with low novelty seeking scores showed the highest impact
of novelty on the responses. Novelty seeking is considered to
be a trait dependent on dopaminergic tone [6] and has been
found to be lower in PD patients compared to controls [13].
The negative correlation therefore seems to be paradoxical
in that it may have been hypothesised that high novelty
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seeking individuals would show the highest impact of the
novel stimuli. However, it may be that as low novelty seeking
predisposes to lower behavioural responses to novelty, the
initial presentation of the novel stimulus produced inhibited
responding. When the level of novelty was reduced (2nd-3rd
presentation) responding was returning to normal therefore
giving a larger diﬀerence on the impact of novelty.
The current study found that harm avoidance scores
were significantly higher in female patients with PD than
male patients. We also found that harm avoidance was
positively and significantly correlated with anxiety scores in
our PD sample. This contributes to findings that there is
a link between the temperament trait of harm avoidance
and anxiety [43]. More surprising was our failure to find
a link between depression and harm avoidance scores, as
this link is commonly reported in nonneurological samples.
One explanation maybe that depression in PD is somewhat
diﬀerent in its manifestation than general depression. For
example it has been argued that depression in PD is indica-
tive of a more advanced and widespread neurodegenerative
illness [44, 45]. Furthermore, it has been observed that symp-
tom profiles and responses to antidepressant medication
are diﬀerent in depressed patients with PD compared to
general depressed patients, suggesting a diﬀerent underlying
pathological mechanism [30]. However, levels of depression
were generally low in our PD sample, with only 15% scoring
in the range of probable clinical depression, and this is an
alternative explanation for our lack of association with harm
avoidance scores.
5. Conclusions
Temperament traits in people with PD may be associated
with aspects of cognitive performance and with aﬀective
disorder. In particular, we provide evidence that harm
avoidance may be more linked to the presence of anxiety
than to depression in people with PD. The trait of novelty
seeking, which is thought to have low expression in PD, was
found to be associated with performance of a cognitive task
involving orientation to visual novelty. These findings extend
our understanding of how temperament interacts with other
manifestations of PD.
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